Matches in Wikidata for { <http://www.wikidata.org/entity/Q37138420> ?p ?o ?g. }
- Q37138420 description "article científic" @default.
- Q37138420 description "article scientifique" @default.
- Q37138420 description "articolo scientifico" @default.
- Q37138420 description "artigo científico" @default.
- Q37138420 description "artículu científicu espublizáu en 2016" @default.
- Q37138420 description "bilimsel makale" @default.
- Q37138420 description "scientific article published on 13 January 2016" @default.
- Q37138420 description "vedecký článok" @default.
- Q37138420 description "vetenskaplig artikel" @default.
- Q37138420 description "videnskabelig artikel" @default.
- Q37138420 description "vědecký článek" @default.
- Q37138420 description "wetenschappelijk artikel" @default.
- Q37138420 description "wissenschaftlicher Artikel" @default.
- Q37138420 description "наукова стаття, опублікована в січні 2016" @default.
- Q37138420 description "научни чланак" @default.
- Q37138420 description "مقالة علمية نشرت في 13 يناير 2016" @default.
- Q37138420 name "Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy" @default.
- Q37138420 name "Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy" @default.
- Q37138420 name "Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy" @default.
- Q37138420 type Item @default.
- Q37138420 label "Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy" @default.
- Q37138420 label "Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy" @default.
- Q37138420 label "Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy" @default.
- Q37138420 prefLabel "Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy" @default.
- Q37138420 prefLabel "Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy" @default.
- Q37138420 prefLabel "Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy" @default.
- Q37138420 P1433 Q37138420-2F01D1AD-9DE7-4858-9791-55D0D91A9EA0 @default.
- Q37138420 P1476 Q37138420-7DFB80EF-6846-453D-ACCA-3C4771CA1179 @default.
- Q37138420 P2093 Q37138420-1B6C8D4A-B5D3-4F86-A54F-05C8360C46CC @default.
- Q37138420 P2093 Q37138420-2AE22550-D114-442E-8CF3-52265BDD64E8 @default.
- Q37138420 P2093 Q37138420-9CD8A729-6969-473D-A958-AC5E667725DE @default.
- Q37138420 P2093 Q37138420-BBCC87C9-98B6-417D-AC22-005673CF2D0D @default.
- Q37138420 P2093 Q37138420-FCEF0E94-E800-48BF-87C4-3B97C4502DA4 @default.
- Q37138420 P2860 Q37138420-05039BC4-A845-43CB-A90D-04AB298D88B1 @default.
- Q37138420 P2860 Q37138420-077ABF69-905F-43E0-9D64-8670FD931639 @default.
- Q37138420 P2860 Q37138420-08E724EE-418A-4234-87AD-B65CDF203467 @default.
- Q37138420 P2860 Q37138420-09638216-76A1-4D4E-9DEE-33BAD563F022 @default.
- Q37138420 P2860 Q37138420-123DB329-A4BA-49BE-86FD-2B9EF1AB4592 @default.
- Q37138420 P2860 Q37138420-197A613A-B9A7-42F7-90EF-612B06635063 @default.
- Q37138420 P2860 Q37138420-1FB352A5-44B7-4231-BB13-CDEAFB4826FB @default.
- Q37138420 P2860 Q37138420-2AA5BA42-E95B-461E-B79C-C28BC178348A @default.
- Q37138420 P2860 Q37138420-2DE73D2B-1C40-42C2-826F-C360248A1918 @default.
- Q37138420 P2860 Q37138420-31B6A744-B0CA-49E5-819B-DB031098A222 @default.
- Q37138420 P2860 Q37138420-32608E92-8DD8-43FB-A3F0-AF420EC59486 @default.
- Q37138420 P2860 Q37138420-36E9ADD3-F8D9-4E12-B4FE-00C8F4B1E141 @default.
- Q37138420 P2860 Q37138420-3841B0E7-A455-4B06-ABEE-8F3CC45CF380 @default.
- Q37138420 P2860 Q37138420-3AA87682-AA4B-4B1C-9A17-399184CE7693 @default.
- Q37138420 P2860 Q37138420-3B7B5A3C-7DF2-4669-A773-E96E4B764C5A @default.
- Q37138420 P2860 Q37138420-55CA633A-18A3-4E1E-B496-906B88A75B1E @default.
- Q37138420 P2860 Q37138420-5ADB7294-A836-4973-A923-5D1DE93DE4B2 @default.
- Q37138420 P2860 Q37138420-5DC98B35-663A-4CC8-BEBA-28A860AD2E1A @default.
- Q37138420 P2860 Q37138420-5FBC8D92-9BF3-47E9-92D8-3ECD1C318FC4 @default.
- Q37138420 P2860 Q37138420-5FE1A03A-1299-4F7B-A0A8-F548D16DB0F0 @default.
- Q37138420 P2860 Q37138420-705DF269-2C12-464B-85D1-AFC51E12C41F @default.
- Q37138420 P2860 Q37138420-74F1B4B7-7C35-4CCC-BDB2-4513C6F6D125 @default.
- Q37138420 P2860 Q37138420-80CDD9E9-F5FD-49B9-8F4B-6C3D5E54E9C4 @default.
- Q37138420 P2860 Q37138420-865059EC-B88D-4B9F-A298-E233D4D660CC @default.
- Q37138420 P2860 Q37138420-8D42FE84-083D-4509-A0FA-D01BF8491C36 @default.
- Q37138420 P2860 Q37138420-8F664DB2-EF10-4A29-954A-16C946D4284D @default.
- Q37138420 P2860 Q37138420-92AAD77B-EC1F-4421-BF22-BE873CB64921 @default.
- Q37138420 P2860 Q37138420-9E0A773E-1CC9-455F-BABF-096AD60809A0 @default.
- Q37138420 P2860 Q37138420-A11B769B-62EC-4904-A122-369D66FA99F9 @default.
- Q37138420 P2860 Q37138420-AD4CB801-D86A-42D8-A50D-C5D86B109100 @default.
- Q37138420 P2860 Q37138420-AE2DBD21-1D6B-45B9-BE05-D9CB5B6A5B79 @default.
- Q37138420 P2860 Q37138420-B8E006FA-5B05-4C15-AE39-D64E88C7843A @default.
- Q37138420 P2860 Q37138420-BF432738-F8E0-40C1-800A-31ACE223E390 @default.
- Q37138420 P2860 Q37138420-C25FC193-9725-4353-8445-5DB1D31669A2 @default.
- Q37138420 P2860 Q37138420-CAC027B1-98F1-4DCB-830C-71EB0198700E @default.
- Q37138420 P2860 Q37138420-D2966242-64D2-4777-A27F-F6E9B3EF99E7 @default.
- Q37138420 P2860 Q37138420-D7CCF87C-6D41-42E8-962E-5E0C6347F42E @default.
- Q37138420 P2860 Q37138420-D96E1733-EFE8-4815-A1EB-243016A2B949 @default.
- Q37138420 P2860 Q37138420-DDA20B78-6053-49C8-94EB-907C0D311479 @default.
- Q37138420 P2860 Q37138420-E59F48BF-A189-4AF0-B337-954F41D99CF1 @default.
- Q37138420 P2860 Q37138420-E6D50C96-2BAC-456D-A6F9-B997B9B11165 @default.
- Q37138420 P2860 Q37138420-EEF0823C-0D31-4037-8591-FBB3B6C68E37 @default.
- Q37138420 P2860 Q37138420-F523AD64-70E8-4B74-80D3-1E1D763A06B5 @default.
- Q37138420 P2860 Q37138420-F6198334-7B96-42EA-AF2A-EB43772985A6 @default.
- Q37138420 P2860 Q37138420-F96C2CCA-1F02-4E8D-BAF2-872AF479220A @default.
- Q37138420 P2860 Q37138420-FB202390-52DD-467F-A133-EA49254CEA2A @default.
- Q37138420 P2860 Q37138420-FF21FBB9-1C26-4FFC-8974-8C0ACBD24596 @default.
- Q37138420 P304 Q37138420-6AE2382A-4117-47D5-BCB5-547148C7A2F0 @default.
- Q37138420 P31 Q37138420-0A9F1453-5A16-4348-A614-8F7213821B86 @default.
- Q37138420 P356 Q37138420-874FED9D-293F-4DA1-8894-1AD64B0953DE @default.
- Q37138420 P433 Q37138420-50177313-0257-4C51-AD31-333322257193 @default.
- Q37138420 P478 Q37138420-D0E29CDB-A7E0-410D-B5BB-73565473F26F @default.
- Q37138420 P50 Q37138420-06A722D0-D512-451F-A2F8-1E2067817B5D @default.
- Q37138420 P50 Q37138420-1278D386-1D02-4D65-8FE0-572BE4142FF2 @default.
- Q37138420 P50 Q37138420-1F1A13BC-8F41-4493-902F-10727EC92C85 @default.
- Q37138420 P50 Q37138420-A760D07E-1B8E-4619-AB7B-34D00F435610 @default.
- Q37138420 P50 Q37138420-D0630B6D-E71D-4DE5-9D90-C11E5D557AD1 @default.
- Q37138420 P50 Q37138420-F3DE45A4-FA54-4B33-9EDC-9814596FA337 @default.
- Q37138420 P577 Q37138420-F539B2A9-83D3-4544-8F8B-9494EEF17529 @default.
- Q37138420 P698 Q37138420-CC2FFF65-32CD-4546-8337-9317549E89E4 @default.
- Q37138420 P921 Q37138420-32D27ECD-5BBE-4BCD-A7B3-377EDA320670 @default.
- Q37138420 P932 Q37138420-23AA1FC7-6F93-4528-91F6-62829EA90B87 @default.
- Q37138420 P356 19420862.2015.1127491 @default.
- Q37138420 P698 26760045 @default.
- Q37138420 P1433 Q6714645 @default.
- Q37138420 P1476 "Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy" @default.
- Q37138420 P2093 "Hao Wang" @default.